Herceptin/Herceptin SC

Metastatic breast cancer (MBC) tumors that overexpress human epidermal growth factor receptor 2 (HER2) as monotherapy for patients who have received ≥1 chemotherapy regimens; in combination w/ paclitaxel or docetaxel for patients who have not received chemotherapy; in combination w/ aromatase inhibitor for patients w/ hormone-receptor +ve metastatic breast cancer. HER2 +ve early breast cancer (EBC) following surgery, chemotherapy (neoadjuvant or adjuvant) & RT (if applicable); following adjuvant chemotherapy w/ doxorubicin & cyclophosphamide in combination w/ paclitaxel or docetaxel; in combination w/ adjuvant chemotherapy consisting of docetaxel & carboplatin; in combination w/ neoadjuvant chemotherapy followed by adjuvant Herceptin, for locally advanced (including inflammatory) breast cancer or tumours >2 cm in diameter. In combination w/ capecitabine or IV 5-fluorouracil & platinum agent for patients w/ HER2 +ve advanced adenocarcinoma of stomach or gastrooesophageal junction who have not received prior anticancer treatment.

Herceptin IV Wkly schedule: Loading dose: Initially 4 mg/kg as 90-min infusion. Subsequent dose: 2 mg/kg as 30-min infusion. Alternative 3-wkly schedule: Loading dose: 8 mg/kg, followed by 6 mg/kg 3 wk later & then 6 mg/kg repeated at 3-wkly intervals as infusions over approx 90 min, or 30-min infusion, if well tolerated. Duration of treatment: MBS & advanced gastric cancer Until disease progression. EBC Max of 1 yr or until disease recurrence. Herceptin SC Fixed dose: 600 mg every 3 wk over 2-5 min every 3 wk. Duration of treatment: EBC Max: 1 yr.

Hypersensitivity.

Infusion-related & pulmonary reactions, cardiac dysfunction. Avoid during pregnancy & lactation.

Infections & infestations, blood & lymphatic system, immune system, metabolism & nutrition, psychiatric, nervous system, eye, cardiac, vascular, resp, thoracic & mediastinal, GI, skin & SC, musculoskeletal & connective tissue, hepatobiliary, ear & labyrinth disorders, general disorders & administration site conditions, injury, positioning & procedural complications.

Targeted Cancer Therapy

L01FD01 - trastuzumab ; Belongs to the class of HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors. Used in the treatment of cancer.

S